UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

The lancet oncology, 2017-07, Vol.18 (7), p.946-957

2017

Volltextzugriff (PDF)

microRNA Signature and Expression of Dicer and Drosha Can Predict Prognosis and Delineate Risk Groups in Neuroblastoma

Cancer research (Chicago, Ill.), 2010-10, Vol.70 (20), p.7841-7850

2010

Volltextzugriff (PDF)

Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO

PloS one, 2020-07, Vol.15 (7), p.e0236115-e0236115

2020

Volltextzugriff (PDF)

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931

Frontiers in immunology, 2018-06, Vol.9, p.1355-1355

2018

Volltextzugriff (PDF)

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia

PloS one, 2014-02, Vol.9 (2), p.e87210

2014

Volltextzugriff (PDF)

High Expression of CAI2, a 9p21-Embedded Long Noncoding RNA, Contributes to Advanced-Stage Neuroblastoma

Cancer research (Chicago, Ill.), 2014-07, Vol.74 (14), p.3753-3763

2014

Volltextzugriff (PDF)

Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy

Journal of experimental & clinical cancer research, 2013-08, Vol.32 (1), p.57-57, Article 57

2013

Volltextzugriff (PDF)

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Clinical cancer research, 2021-04, Vol.27 (8), p.2179-2189

2021

Volltextzugriff (PDF)

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2160-2169

2020

Volltextzugriff (PDF)

Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth

PloS one, 2014-02, Vol.9 (2), p.e88219-e88219

2014

Volltextzugriff (PDF)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931

Frontiers in immunology, 2018-07, Vol.9, p.1641-1641

2018

Volltextzugriff (PDF)

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Clinical cancer research, 2018-01, Vol.24 (1), p.189-196

2018

Volltextzugriff (PDF)

Abstract 980: The long non-coding RNA CAI2 is a tumor suppressor gene

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.980-980

2016

Volltextzugriff (PDF)

MPDA: microarray pooled DNA analyzer

BMC bioinformatics, 2008-04, Vol.9 (1), p.196-196, Article 196

2008

Volltextzugriff (PDF)

Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue

Free radical biology & medicine, 2014-04, Vol.69, p.167-171

2014

Volltextzugriff (PDF)

Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing

Leukemia research, 2009-11, Vol.33 (11), p.1562-1566

2009

Volltextzugriff (PDF)

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

Blood, 2002-11, Vol.100 (9), p.3319-3324

2002

Volltextzugriff (PDF)

Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia

Cancer research (Chicago, Ill.), 1997-03, Vol.57 (5), p.832-836

1997

Volltextzugriff (PDF)

Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7333-7338

2001

Volltextzugriff (PDF)

Abstract 158: The p16/ARF intron 2 imbedded long non-coding RNA CAI2 is highly expressed in tumor cells and modulates chromatin structure

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.158-158

2015

Volltextzugriff (PDF)

EFA (9-β-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine

Blood, 2006-02, Vol.107 (3), p.898-903

2006

Volltextzugriff (PDF)

Ras Activation in Normal White Blood Cells and Childhood Acute Lymphoblastic Leukemia

Clinical cancer research, 2000-05, Vol.6 (5), p.1804-1810

2000

Volltextzugriff (PDF)

Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma

Genes chromosomes & cancer, 2004-12, Vol.41 (4), p.297-308

2004

Volltextzugriff (PDF)

Universal Inactivation of Both p16 and p15 but not Downstream Components Is an Essential Event in the Pathogenesis of T-Cell Acute Lymphoblastic Leukemia

Clinical cancer research, 2000-04, Vol.6 (4), p.1219-1228

2000

Volltextzugriff (PDF)

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro

Cancer research (Chicago, Ill.), 1999-04, Vol.59 (7), p.1492-1497

1999

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(29)
Humans
(28)
Biological And Medical Sciences
(19)
Oncology
(18)
Medical Sciences
(14)
Child
(12)
Animals
(10)
Base Sequence
(8)
Infant
(8)
Molecular Sequence Data
(8)
Neuroblastoma
(8)
Pharmacology. Drug Treatments
(8)
Antineoplastic Agents
(7)
Biochemistry & Molecular Biology
(7)
Cell Line, Tumor
(7)
Cyclin-Dependent Kinase Inhibitor P16 - Genetics
(7)
Gene Expression Regulation, Neoplastic
(7)
Immunotherapy
(7)
Leukemia-Lymphoma, Adult T-Cell - Genetics
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

microRNA Signature and Expression of Dicer and Drosha Can Predict Prognosis and Delineate Risk Groups in Neuroblastoma

Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia

High Expression of CAI2, a 9p21-Embedded Long Noncoding RNA, Contributes to Advanced-Stage Neuroblastoma

Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group

Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Abstract 980: The long non-coding RNA CAI2 is a tumor suppressor gene

MPDA: microarray pooled DNA analyzer

Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue

Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia

Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication

Abstract 158: The p16/ARF intron 2 imbedded long non-coding RNA CAI2 is highly expressed in tumor cells and modulates chromatin structure

EFA (9-β-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine

Ras Activation in Normal White Blood Cells and Childhood Acute Lymphoblastic Leukemia

Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma

Universal Inactivation of Both p16 and p15 but not Downstream Components Is an Essential Event in the Pathogenesis of T-Cell Acute Lymphoblastic Leukemia

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro

Suchergebnisse filtern